StockData
Integrated BioPharma Inc logo

Integrated BioPharma Inc (INBP) stock

INBPOTCPharmaceutical PreparationsFiscal year ends June 30
Financials through Q4 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 13, 2026Score 6/30
$0.18+0.00 (0.00%)

Close on Oct 19, 2026Market cap $5.59MP/E –Yield –

Integrated BioPharma free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

Integrated BioPharma's free cash flow for the twelve months ending Jun 30, 2026 was $895.00K, down 52.2% year over year. For fiscal 2026 it was $895.00K, down 52.2% from the year before. The highest annual figure on record is $3.61M in fiscal 2022.

Annual free cash flow

PeriodPeriod endValueChange
FY2026Jun 30, 2026$895.00K-52.2%
FY2025Jun 30, 2025$1.87M+380.5%
FY2024Jun 30, 2024$390.00K-65.1%
FY2023Jun 30, 2023$1.12M-69.0%
FY2022Jun 30, 2022$3.61M+30.9%
FY2021Jun 30, 2021$2.76M+144.9%
FY2020Jun 30, 2020$1.13M–
FY2019Jun 30, 2019-$86.00K-109.3%
FY2018Jun 30, 2018$921.00K+1215.7%
FY2017Jun 30, 2017$70.00K–
FY2016Jun 30, 2016-$703.00K–
FY2015Jun 30, 2015-$348.00K-120.5%
FY2014Jun 30, 2014$1.70M–
FY2013Jun 30, 2013-$1.47M–
FY2012Jun 30, 2012-$926.00K-1117.6%
FY2011Jun 30, 2011$91.00K–

Quarterly free cash flow

Change is against the same quarter a year earlier.

Periods
PeriodPeriod endValueChange
Q4 FY2026CQ2 2026Jun 30, 2026-$1.34M-323.5%
Q3 FY2026CQ1 2026Mar 31, 2026$517.00K+3.4%
Q2 FY2026CQ4 2025Dec 31, 2025$593.00K+244.8%
Q1 FY2026CQ3 2025Sep 30, 2025$1.13M+87.7%
Q4 FY2025CQ2 2025Jun 30, 2025$601.00K–
Q3 FY2025CQ1 2025Mar 31, 2025$500.00K-61.5%
Q2 FY2025CQ4 2024Dec 31, 2024$172.00K–
Q1 FY2025CQ3 2024Sep 30, 2024$601.00K-52.9%
Q4 FY2024CQ2 2024Jun 30, 2024-$332.00K–
Q3 FY2024CQ1 2024Mar 31, 2024$1.30M-10.7%
Q2 FY2024CQ4 2023Dec 31, 2023-$1.85M–
Q1 FY2024CQ3 2023Sep 30, 2023$1.28M+35.4%
Q4 FY2023CQ2 2023Jun 30, 2023-$1.20M-145.1%
Q3 FY2023CQ1 2023Mar 31, 2023$1.45M+173.3%
Q2 FY2023CQ4 2022Dec 31, 2022-$76.00K–
Q1 FY2023CQ3 2022Sep 30, 2022$942.00K-52.2%
Q4 FY2022CQ2 2022Jun 30, 2022$2.67M+370.5%
Q3 FY2022CQ1 2022Mar 31, 2022$532.00K-53.4%
Q2 FY2022CQ4 2021Dec 31, 2021-$1.57M–
Q1 FY2022CQ3 2021Sep 30, 2021$1.97M+5.6%
Q4 FY2021CQ2 2021Jun 30, 2021$567.00K–
Q3 FY2021CQ1 2021Mar 31, 2021$1.14M-53.1%
Q2 FY2021CQ4 2020Dec 31, 2020-$818.00K–
Q1 FY2021CQ3 2020Sep 30, 2020$1.87M+14.6%
Q4 FY2020CQ2 2020Jun 30, 2020-$2.27M-502.5%
Q3 FY2020CQ1 2020Mar 31, 2020$2.43M+340.9%
Q2 FY2020CQ4 2019Dec 31, 2019-$670.00K–
Q1 FY2020CQ3 2019Sep 30, 2019$1.63M+183.0%
Q4 FY2019CQ2 2019Jun 30, 2019$563.00K–
Q3 FY2019CQ1 2019Mar 31, 2019$552.00K-16.5%
Q2 FY2019CQ4 2018Dec 31, 2018-$1.78M–
Q1 FY2019CQ3 2018Sep 30, 2018$575.00K-61.6%
Q4 FY2018CQ2 2018Jun 30, 2018-$206.00K–
Q3 FY2018CQ1 2018Mar 31, 2018$661.00K+49.5%
Q2 FY2018CQ4 2017Dec 31, 2017-$1.07M-204.1%
Q1 FY2018CQ3 2017Sep 30, 2017$1.50M–
Q4 FY2017CQ2 2017Jun 30, 2017-$835.00K–
Q3 FY2017CQ1 2017Mar 31, 2017$442.00K–
Q2 FY2017CQ4 2016Dec 31, 2016$1.03M–
Q1 FY2017CQ3 2016Sep 30, 2016-$567.00K–

More Integrated BioPharma figures

See a number that looks wrong?